Group 1 - The financial vulnerability of overseas tech giants is becoming apparent, leading the market to focus on high-certainty assets, with a shift in the A-share market towards a rebalancing of styles [1][2] - The development gap in the tech industry has transitioned from US-based computing infrastructure to China's advantages in power, manufacturing, and general infrastructure, indicating a repricing of Chinese assets [2][3] - The energy transition over the past few years has involved the entire industry chain, creating advantages not limited to the new energy sector, which forms the basis and opportunity for the current market expansion [1][2] Group 2 - The A-share market is experiencing a style rebalancing, with the TMT sector lagging behind sectors benefiting from overseas power shortages, such as power equipment and chemicals [2][3] - The market is beginning to recognize the true value of China's substantial capacity built for energy transition, which not only leads globally in new energy system construction but also provides a stable and low-cost energy advantage for the high-end transformation of Chinese manufacturing [2][3] Group 3 - The current high elasticity in the power equipment market is due to long-term undervaluation from previous overcapacity, with a dual recovery in valuation and performance driven by overseas power shortages [3][5] - The chemical sector is identified as a significant direction for market expansion, as it includes core materials for power equipment and has companies positioned to leverage integrated advantages in the energy transition [3][5] Group 4 - The correlation between chemical sub-sectors and power equipment stock prices during the 2020-2022 new energy wave indicates that industries with high relevance to the new energy chain are likely to benefit from the ongoing energy transition [4][5] - Recommendations include focusing on titanium dioxide, organic silicon, coatings, modified plastics, and membrane materials, which are closely tied to the new energy sector and are positioned for recovery as traditional business conditions improve [4][5] Group 5 - The global power shortage is expected to increase production costs for high-energy-consuming industries, enhancing the competitive advantage of Chinese industries with relatively abundant power resources [5][6] - The market structure is evolving, with a new consensus emerging around the revaluation of physical assets and China's manufacturing advantages, driven by the recovery of manufacturing momentum and expansion of real economy investments [6][7]

| 证券代码：600109 | 证券简称：国金证券 | | 公告编号：临 2025－88 | | --- | --- | --- | --- | | 债券代码：241898 | 债券简称：24 04 | 国金 | | 国金证券股份有限公司 关于"24 国金 04"公司债券付息完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 国金证券股份有限公司（以下简称"本公司"）于 2024 年 11 月 7 日发行了国金证券股份有限公司 2024 年面向专业投资者公开发 行公司债券（第四期）（债券简称：24 国金 04、债券代码：241898）, 发行总额为人民币 15 亿元，票面利率为 2.28%，发行期限为 3 年。 详 见 公 司 于 2025 年 10 月 31 日 登 载 于 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn）的《国金证券股份有限公司 2024 年面向 专业投资者公开发行公司债券（第四期）2025 年付息公告》。 国金证券股份有限公司 董事会 二〇二五年十一月十日 ...

Core Viewpoint - The lithium battery industry is experiencing unprecedented development opportunities driven by a technological revolution and market demand resonance, particularly with breakthroughs in solid-state battery technology and explosive growth in the global energy storage market [1] Group 1: Industry Outlook - The lithium battery sector is expected to see a significant increase in capital expenditure (Capex) driven by solid-state battery technology breakthroughs by 2025, alongside continuous supply-side reforms and capacity consolidation from 2023 to 2025, leading to a potential reversal in supply-demand dynamics and price increases across multiple segments [2] - The lithium battery midstream is entering a "recovery-prosperity" phase in 2024-2025, with revenue and inventory trends indicating an upward trajectory since Q1 2024, suggesting a prosperous inventory cycle by Q3 2025 [2] - New technologies and applications are expected to create a second growth wave for lithium batteries, with solid-state batteries being a long-term strategic focus that will reshape processes and material systems, transitioning to pilot production lines by 2025 [2] Group 2: Market Dynamics - The industry is characterized by clear competitive advantages for leading products and cost structures, with top players likely to achieve full capacity utilization first, ensuring the most reliable performance and flexibility [3] - The supply chain for lithium hexafluorophosphate, energy storage batteries, and separators is expected to see price increases, indicating high-growth potential in these segments [3] Group 3: Production Tracking - Domestic battery sample enterprises are projected to produce 144.14 GWh in November, reflecting a 1.76% month-on-month increase [4] - Overseas battery sample enterprises are expected to maintain production at 24.4 GWh, showing no month-on-month change [5] - Production of cathodes is expected to reach 176,600 tons, up 7.35% month-on-month, while anodes are projected at 155,000 tons, down 1.89% month-on-month [6][7] - Separator production is anticipated at 1.89 billion square meters, up 3.56% month-on-month, and electrolyte production at 107,000 tons, up 8% month-on-month [8][9] Group 4: Investment Recommendations - Focus on the following key areas: 1) Pilot production lines for semi-solid and solid-state batteries, along with core equipment and material specifications [9] 2) New solid-state battery technologies such as lithium metal anodes and dry electrodes [9] 3) Price increase opportunities in segments like lithium hexafluorophosphate, energy storage batteries, separators, and anodes [9] 4) Explosive demand from data centers and core suppliers for energy storage, BBU, and UPS batteries [9] 5) Sodium-ion batteries gaining traction in energy storage and two-wheeler applications [9] Group 5: Lithium Market Dynamics - In the short term, the lithium market is experiencing high supply levels with strong demand from both the electric vehicle and energy storage sectors, leading to increased material demand and a low inventory situation [10] - Monthly demand for independent domestic energy storage and overseas AI storage is expected to remain above 120,000 tons, with a monthly inventory reduction of 8,000 to 10,000 tons, providing ongoing price support [10] - The demand growth forecast for energy storage in 2026 has been revised upward, indicating an improving supply-demand balance and a potential acceleration in inventory reduction [10]

Core Insights - The lithium battery industry chain is experiencing unprecedented development opportunities driven by a confluence of technological revolution and market demand [1] Technological Developments - Significant breakthroughs in solid-state battery technology are reconstructing the industry's ceiling [1] - The next phase goal for solid-state battery technology is to address the high sensitivity of energy storage systems to cycle life and cost [1] Market Dynamics - The explosive growth of the global energy storage market is providing unexpected capacity space for the lithium battery industry [1] - The vast application scenarios and capital return from the energy storage market are accelerating the research and industrialization of cutting-edge technologies like solid-state batteries [1] Industry Outlook - The lithium battery industry chain is expected to undergo a value reassessment in this wave of technological and market changes [1]

Report Industry Investment Rating No relevant content provided. Core Viewpoints of the Report In October, the approval of urban investment bonds showed characteristics of a slight decline in registration quota, a marginal acceleration in the approval rhythm, and a slight decline in the scale of terminated projects, with the overall financing rhythm slowing down. The supply - structure differentiation and the gap between strong and weak urban investment bonds further widened. The approval rhythm showed marginal relaxation, but the approval for urban investment platforms with different qualifications remained significantly differentiated. The establishment of the Debt Management Department by the Ministry of Finance in 2025 indicates stricter debt supervision, and it is recommended to continue to monitor the implementation of policy tools and relevant regulatory dynamics of the Debt Management Department [6][53]. Summary by Catalog 1. Registration Status: Slight Decline in Urban Investment Registration Quota - Overall registration: In October, the registration quota of urban investment platforms decreased slightly. The registration scale of the exchange decreased significantly, from 2338 billion yuan to 1868 billion yuan, while that of DCM increased slightly, from 1886 billion yuan to 2065 billion yuan [12]. - By administrative level: The registration scales of provincial and municipal urban investment platforms decreased. The proposed issuance scale of provincial urban investment registration projects dropped from 945 billion yuan to 631 billion yuan, and that of prefecture - level cities dropped from 1588 billion yuan to 1302 billion yuan. The proposed issuance scale of district - level urban investment registration projects increased from 1691 billion yuan to 2000 billion yuan, and its three - month moving average proportion rose to 42% [15]. - By district and county qualifications: The registration scale of districts and counties with weak qualifications decreased significantly. The registration scale of district - level platform bonds with a budget revenue of less than 5 billion yuan dropped from 675 billion yuan to 408 billion yuan, and the three - month moving average proportion decreased to 39.2% [18]. - By province: The scales in regions such as Zhejiang, Shandong, and Sichuan decreased significantly month - on - month. The scales in Sichuan, Anhui, and Shaanxi continued to decline. The scale growth in Jiangsu was mainly at the district - level, while that in Tianjin increased significantly month - on - month [20]. 2. Approval Feedback: Marginal Acceleration in Urban Investment Bond Approval - By issuance venue: In October, the DCM and exchange approval rhythms for urban investment bonds both accelerated. The number of effective sample bonds registered in DCM was 300, a significant decrease from the previous month, and that in the exchange was 81, also a significant decrease. The average number of feedbacks in DCM increased from 2.4 to 2.5 times, and the feedback time decreased from 41.5 days to 40.6 days. The average number of feedbacks in the exchange decreased from 4.1 to 3.7 times, and the feedback time decreased from 80.6 days to 70 days [28]. - By issuance method and level: The feedback times of public and private urban investment corporate bonds in prefecture - level cities and district - level cities decreased to varying degrees [33]. - By province: The approval rhythms in Jiangxi, Shaanxi, Fujian and other places accelerated significantly. The approval speeds in Zhejiang, Anhui, and Shanxi continued to improve, while the approval feedback days in Sichuan, Hubei, Guangdong and other places were significantly extended [37]. - By district and county qualifications: The approval rhythm of platform bonds in districts and counties with weak qualifications slowed down. The feedback days of district - level platforms with a general budget revenue of less than 5 billion yuan increased from 70.3 days to 72.6 days, lower than the average of last year. The approval rhythms of district - level platforms with a general budget revenue of 5 - 8 billion yuan and 10 - 30 billion yuan accelerated significantly [39]. 3. Terminated Issuance: Slight Decline in the Scale of Terminated Projects - Overall situation: In October, the scale of terminated projects decreased slightly. The proposed issuance scale of terminated urban investment bonds decreased from 13 billion yuan to 12.5 billion yuan, and the number of terminated projects decreased from 9 to 6. The terminated scale of district - level urban investment bonds decreased significantly, and its three - month moving average proportion decreased to 46%. The scale of terminated projects at the municipal level increased significantly, and there were no terminated projects at the provincial level. The three - month moving average proportion of the number of terminated projects in districts and counties with weak qualifications (local budget revenue of less than 5 billion yuan) continued to decline to 30.6% [42]. - By province: Terminated projects of urban investment platforms mainly occurred in Shandong, Henan, and Hebei. The scale of terminated projects in Shandong was mainly at the district - level platform, while those in Henan and Hebei were mainly affected by prefecture - level platforms [50].

Core Insights - Guojin Securities maintains a "Buy" rating for BeiGene (06160), highlighting its leadership in the domestic biopharma sector and significant global expansion, with both commercialization and R&D reaching critical inflection points [1] - The company’s core products are experiencing rapid growth, and its international strategy is beginning to yield results, with an anticipated increase in R&D catalysts [1] - For Q3 2025, the company reported total revenue of $1.4 billion, a year-on-year increase of 41%, and a GAAP net profit of $125 million [1] Financial Performance - The updated guidance for 2025 includes total revenue expectations of $5.1-5.3 billion, GAAP operating expenses of $4.1-4.3 billion, and a gross margin in the mid-to-high 80% range, with positive GAAP net profit and free cash flow for the year [1] - In Q3 2025, the sales of Zanubrutinib reached $1.04 billion, reflecting a year-on-year growth of 51% and a quarter-on-quarter increase of 10%, establishing it as a leader in the global BTKi market [1] - The U.S. market remains the primary revenue source for Zanubrutinib, generating $739 million, a year-on-year increase of 47% and a quarter-on-quarter increase of 8% [1] - The European market showed significant growth, with sales of $163 million, a year-on-year increase of 68% and a quarter-on-quarter increase of 8% [1] R&D Milestones - Upcoming R&D milestones include the submission of Sotigalimab in the U.S. in H2 2025, initiation of head-to-head trials for Zanubrutinib in CLL in H1 2026, and the start of Phase III trials for multiple indications [2] - The company plans to read out potential registration clinical data for BTKCDAC in H1 2026 and will not pursue second-line development for CDK4 inhibitors, instead focusing on first-line HR+HER2- breast cancer trials [2] - POC data readouts are expected in H1 2026 for FGFR2b ADC, pan-KRASi, EGFRCDAC, and CDK2i, with additional data readouts in H2 2026 for PRMT5i+MAT2Ai and EGFR/MET/MET tri-antibodies [2]

Core Viewpoint - Guojin Securities maintains a "Buy" rating for BeiGene (06160), highlighting its leadership in the domestic biopharma sector and significant global expansion, with both commercialization and R&D reaching critical turning points [1] Financial Performance - In Q3 2025, the company achieved total revenue of $1.4 billion, a year-on-year increase of 41%, and a GAAP net profit of $125 million [1] - The updated guidance for 2025 includes total revenue of $5.1-5.3 billion, GAAP operating expenses of $4.1-4.3 billion, and a gross margin in the high 80-90% range, with positive GAAP net profit and free cash flow for the year [1] Product Sales - In Q3 2025, the sales of Zanubrutinib reached $1.04 billion, showing a year-on-year growth of 51% and a quarter-on-quarter increase of 10%, establishing it as a leader in the global BTKi market [1] - The U.S. market contributed significantly, with sales of $739 million, a year-on-year increase of 47% and a quarter-on-quarter increase of 8%, while the European market saw a sales increase of 68% year-on-year, reaching $163 million [1] - Sales of Tislelizumab in Q3 2025 amounted to $191 million, reflecting a year-on-year growth of 17% [1] R&D Milestones - Upcoming R&D milestones include the submission of Sotigalimab in H2 2025 in the U.S., initiation of head-to-head clinical trials for Zanubrutinib and Acalabrutinib in H1 2026, and the start of Phase III trials for MM in H2 2026 [2] - The company plans to read out potential registration clinical data for BTKCDAC in H1 2026 and will not pursue second-line development for CDK4 inhibitors, instead focusing on first-line HR+HER2- breast cancer trials [2] - POC data readouts are expected in H1 2026 for FGFR2b ADC, pan-KRASi, EGFRCDAC, and CDK2i, with additional data readouts in H2 2026 for PRMT5i+MAT2Ai and EGFR/MET/MET tri-antibodies [2]

Group 1 - The Shanghai Composite Index opened lower but rebounded to surpass 4000 points during the morning session, closing down 0.16% [1] - The Securities ETF (159841) saw a decline of 0.79% with a half-day trading volume of 263 million yuan, making it the top performer among similar products in the Shenzhen market [1] - The Securities ETF has experienced net inflows for 15 out of the last 20 days, accumulating over 1 billion yuan in total [1] Group 2 - The A-share margin financing balance reached approximately 2.4916 trillion yuan as of November 4, representing 2.57% of the circulating market value, maintaining above 2.5% for 19 consecutive trading days [2] - The margin financing amount for listed brokers increased significantly from 1.56 trillion yuan at the end of June to over 2 trillion yuan [2] - Brokers are expected to benefit from improved policies and reforms, with opportunities for growth through both external and internal development strategies [2]

Core Points - Guojin Securities Co., Ltd. will begin paying the principal and final interest of its publicly issued corporate bonds on November 14, 2025 [2][3] - The bonds have a total issuance amount of 1 billion yuan and a maturity period of 3 years with a coupon rate of 2.85% [4][5] Summary by Sections Bond Issuance Details - The bond is named "Guojin Securities Co., Ltd. 2022 Publicly Issued Corporate Bonds (First Phase)" with the code 138566.SH [4] - The total issuance amount is 1 billion yuan [4] - The bond has a maturity of 3 years and a coupon rate of 2.85% [4] Payment Schedule - The interest payment period for the current year is from November 14, 2024, to November 13, 2025 [3] - The principal repayment amount per bond is 1,000 yuan, with an interest payment of 28.50 yuan (including tax) [3] - The bond registration date is November 13, 2025, and the payment date is November 14, 2025 [4][5] Taxation Information - Individual investors are required to pay a personal income tax on the interest income from the bonds at a rate of 20% [8] - The tax will be withheld at the time of interest payment by the respective payment institutions [8] - Foreign institutional investors are temporarily exempt from corporate income tax and value-added tax on interest income until December 31, 2025 [7]

| | | 债券代码：138566 债券简称：22 国金 G1 国金证券股份有限公司 1、债券名称：国金证券股份有限公司 2022 年面向专业投资者公 开发行公司债券(第一期) 2022 年面向专业投资者公开发行公司债券（第一期） 2025年本息兑付及摘牌公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 国金证券股份有限公司 2022 年面向专业投资者公开发行公司债 券(第一期)（以下简称"本期债券"），将于 2025 年 11 月 14 日开始 支付自 2024 年 11 月 14 日至 2025 年 11 月 13 日期间的最后一个年度 利息和本期债券本金。为保证还本付息工作的顺利进行，现将有关事 宜公告如下： 2、债券简称：22 国金 G1 3、债券代码：138566.SH 4、发行人：国金证券股份有限公司 债权登记日：2025 年 11 月 13 日 本息兑付日：2025 年 11 月 14 日 债券摘牌日：2025 年 11 月 14 日 5、发行总额：10 亿元 一、本期债券的基本情况 6 ...